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Abstract
Background: During maintenance treatment, Dutch pediatric patients with medium-
risk (MR) acute lymphoblastic leukemia (ALL) receive intravenous chemotherapy and
cyclic dexamethasone. Dexamethasone affects child’s sleep and behavior. Standard-
risk (SR) patients only receive oral chemotherapy, without dexamethasone. Effects of
stratified therapy on parents are not well known. This study compares parental sleep,
distress and quality of life (QoL) with the general population, between MR and SR
groups, and on- and off-dexamethasone (MR group).
Procedure: One year after diagnosis, parents of MR patients completed the Med-
ical Outcomes Study (MOS) sleep, distress thermometer for parents and Short
Form-12 (SF-12) twice; once on-dexamethasone and once off-dexamethasone. SR
parents completed one measurement. Sleep problems, distress and QoL scores
(off-dexamethasone) were compared to reference values and between MR and SR.
Score differences on- and off-dexamethasone were assessed by multilevel regression
analysis.
Results: Parents (80% mothers) of 121 patients (57% males; 75% MR, 25% SR) com-
pleted 191 measurements. Compared to reference values, parents reported more
sleep disturbances, higher distress, and lower mental QoL. Additionally, MR parents
reported clinical distress (score ≥ 4), whereas SR parents (on average) did not (mean
4.8 ± 2.4 vs 3.5 ± 2.4, P = .02). Within the MR group, outcomes did not significantly
differ on- and off-dexamethasone.
Conclusions: Parents of ALL patients report sleep problems, high distress, and QoL
impairment. Within the MR group, parental functioning did not differ on- and off-
dexamethasone. However, MR parents reported clinical distress more often than
SR parents, possibly reflecting differences in prognostic estimates and treatment
burden. This perhaps includes the overall strain of cyclic dexamethasone. This study
Abbreviations: ALL, acute lymphoblastic leukemia; CBT-I, cognitive behavioral therapy for insomnia; CNS, central nervous system; DCOG, Dutch ChildhoodOncology Group; HR, high risk; MCS,
mental component summary score;MOS,Medical Outcomes Study;MR, medium risk; PCS, physical component summary score; QoL, quality of life; SF-12, Short Form-12; SLP-9, nine-item sleep
problems index; SR, standard risk
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highlights the need for psychosocial support throughout treatment, regardless of risk
stratification.
KEYWORDS
ALL, dexamethasone, parents, psychosocial, quality of life, sleep
1 INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common type of child-
hood cancer. Survival rates have reached over 90% due to the estab-
lishment of intense chemotherapy regimens and enhanced support-
ive care.1 However, chemotherapeutic agents can cause significant
short- and long-term side effects; hence, treatment intensity is ideally
adjusted according to an individual patient’s risk profile.1,2
In theNetherlands, themajority of pediatric patientswithALL (from
1 year of age) are treated according to the frontline Dutch Childhood
Oncology Group (DCOG) ALL11 protocol (since 2012).3 This proto-
col distinguishes three risk groups: the most favorable standard-risk
(SR) group, comprising approximately 25% of patients; the medium-
risk (MR) group, comprising approximately 70% of patients; and the
high-risk (HR) group, only comprising about 5% of patients.
The induction phase of treatment is generally the same across all
risk groups. After induction, either directly or during central nervous
system (CNS)-targeted therapy, HR patients continue with a different,
more intense treatment regimen, with or without an allogenic stem
cell transplant. Differentiation between SR and MR treatment occurs
after CNS-targeted therapy. Total treatment duration across these risk
groups is generally 2 years.3
During SR maintenance, patients only receive oral chemotherapy
(dailymercaptopurine andweeklymethotrexate) at home, and visit the
hospital every 2-3 weeks. Patients in MR maintenance receive daily
oral mercaptopurine at home, weekly intravenousmethotrexate at the
hospital, and intravenous vincristine (with asparaginase during the first
4 months) every 3 weeks. Vincristine is known for inducing peripheral
neuropathy, possibly leading to pain and obstipation.4 Furthermore,
MR patients receive intrathecal chemotherapy under procedural anes-
thesia every 18weeks. And finally, patients inMRmaintenance receive
cyclic dexamethasone treatment, as opposed to those in SR mainte-
nance,whichmeans 5days of high-dose dexamethasone (6mg/m2/day)
every 3weeks during approximately 1.5 years.3
Dexamethasone is a glucocorticoid with many well-known adverse
effects on the child’s behavior, sleep, and general quality of life
(QoL).5–9 The recurrent pattern of this treatment puts a high burden
on both the patient and their families, certainly on parents. In qualita-
tive research, parents have reported very high emotional impact of the
dexamethasone treatment and identified it as themajor stressor during
the overall relatively stable maintenance period.10,11
In general, it is known that parents of pediatric cancer patients are
at risk for impaired QoL, both during and after treatment, and that
major determinants of adverse QoL outcomes are sleep problems
and distress.12–17 Specifically during ALL maintenance treatment,
reports on parental psychosocial functioning are sparse, but they
show high prevalence of sleep disturbances and significant emotional
distress.18–23
However, quantitative studies regarding the specific effects of cyclic
dexamethasone during ALL maintenance on parental outcomes are
lacking. Additionally, although different risk groups entail different
prognostic estimates and treatment intensity, which may influence
parental well-being, no previous studies have been performed on the
general effects of ALL risk-group stratification on parents’ sleep, dis-
tress, andQoL.
Since the child’s well-being is very closely related to parents’ well-
being (and vice versa), it is for the benefit of the whole family to opti-
mize parental functioning.24 Yet more knowledge is needed first. This
study therefore aims to assess sleep, distress, and QoL in parents of
patients with ALL during maintenance therapy, and compare this with
the general population and between the MR and SR groups. Further-
more, this study aims to assess differences within the MR group, com-
paring a weekwith and aweekwithout dexamethasone.
2 METHODS
Results of this study were derived from the nationwide, longitudinal
ALL11 add-on SLeep in children with Acute lymphoblastic leukemia
And their Parents (SLAAP) study (SLEEP). A detailed description of the
study is described elsewhere.25 Pediatric patients from 2 years of age
and their parents were eligible, if sufficiently fluent in Dutch to com-
plete questionnaires independently, and if the child was being treated
according to theDCOGALL11protocol inoneof theparticipatingpedi-
atric oncology centers in the Netherlands. Parents as well as patients
aged 12 years and above provided written informed consent. Parental
outcomes were assessed with questionnaires.
Assessment took place approximately 1 year after diagnosis, dur-
ing the relatively stable phase in maintenance therapy. During this
phase of treatment, MR patients no longer received asparaginase. Par-
ents of SR andHR patients completed onemeasurement, whereas par-
ents of MR patients completed two; one in a week with dexametha-
sone (on-dexa), and one in a week without (off-dexa). Families could
choose to start with either the on-dexa or the off-dexa measurement
(Figure 1). The on-dexa measurement started on the first day of the
5 days of dexamethasone treatment (child’s actigraphy assessment);
yet, the parental outcomes described in this manuscript were assessed
with questionnaires, which could be completed at any day during the
RENSEN ET AL. 3 of 8
F IGURE 1 Schedule of measurements with andwithout dexamethasone (medium-risk patients). DEX, dexamethasone; light blue bars reflect
themeasurement weekwith dexamethasone, and dark blue bars themeasurement without dexamethasone
F IGURE 2 Overview of measurements completed by parents of
standard- andmedium-risk patients, respectively
measurement week. Questionnaires were completed by one parent,
on paper or online through a secured portal (respondent’s preference).
Since only one HR patient participated, data from this patient and his
parents were excluded from analysis in this manuscript.
The Institutional Review Board of the Erasmus Medical Center
approved this study (MEC-2012-187).
2.1 Outcome measures
2.1.1 Parental sleep
The Medical Outcomes Study (MOS) sleep scale is a 1-week, vali-
dated and reliable retrospective instrument with 12 items and six
subscales.26 The latter include: (a) sleep disturbance (problems with
falling asleep initially and falling back asleep after nightly awakenings,
four items); (b) sleep adequacy (getting enough sleep and feeling
rested in the morning, two items); (c) daytime somnolence (daytime
naps and feeling somnolent, three items); (d) snoring (one item); (e)
awakening short of breath orwith headache (one item), and (f) quantity
of sleep (one item). Quantity of sleep is scored as the average hours
slept per night, with optimal sleep duration defined as between 7
and 8 h per night. The other scales are scored on a 0-100 possible
range, with higher scores indicatingmore sleep problems on each scale
(except for sleep adequacy, where higher scores reflect better sleep).
Nine of these items (all but the items on quantity of sleep, snoring,
and daytime naps) are scored into a sum score, the nine-item sleep
problems index (SLP-9). The SLP-9 ranges from 0 to 100 and includes
all items except those on quantity of sleep, snoring, and daytime naps;
thus, representing symptoms consistent with insomnia-like troubled
initiation or maintenance of sleep, and daytime consequences of poor
sleep. The SLP-9 score is presented in this study. The MOS manual
was used to construct the score and handle missing values.27 Dutch
reference values for healthy adults are available.28
2.1.2 Parental distress
The distress thermometer for parents (DT-P) consists of a thermome-
ter onwhich parents rate their overall distress regarding physical, emo-
tional, social, and practical issues on a scale of 0-10, with 4 or higher
indicating clinical levels of distress.29 The validity and internal consis-
tencyof this instrument are good.29 Dutch referencevalues for parents
of healthy children are available.30
2.1.3 Parental QoL
The Short Form-12 (SF-12) is a generic QoL instrument. It measures
functional health and well-being by means of two summary scores: the
physical component summary score (PCS) andmental component sum-
mary score (MCS). The MCS and PCS are norm-based standardized
summary scoreswith amean of 50 and standard deviation (SD) of 10 in
the general US population.31 Higher scores indicate better QoL. Miss-
ing values were not imputed. The SF-12 has adequate validity and reli-
ability, and age- and sex-specific Dutch reference values for healthy
adults are available.31,32
2.2 Statistical analysis
2.2.1 Description of parental sleep, distress,
and QoL
Mean SLP-9 and distress scores for all parents (using the off-dexa
assessment in MR parents) were compared to reference values with
one-sided t-tests. ForQoL, age- and sex-specific reference values were
used and Z-scores were calculated. Additionally, prevalence rates of
clinically relevant sleep problems, clinical distress, and impaired QoL
were assessed. For distress, the previously established cut-off of 4 or
higher was used to indicate clinical levels of distress. For sleep and
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QoL, SD cut-offs were used, which have been described in previous
literature.33 Parents with SLP-9, MCS, or PCS scores > 1 SD above
theDutch reference’smeanwere considered to have clinically relevant
sleep problems or impaired (physical/mental) QoL, respectively.
2.2.2 Comparison of parental sleep, distress,
and QoL between the SR and MR groups
Mean scores of SR parents were compared to mean off-dexa scores
for MR parents by linear regression analysis. Considering the differ-
ences in psychosocial outcomes between mothers and fathers,12 anal-
yses were corrected for parent’s sex.
2.2.3 Comparison of parental sleep, distress,
and QoL on- versus off-dexa (MR group)
Mean on-dexa scores for MR parents were compared to off-dexa
scores by multilevel linear regression analysis with random intercept.
Since in 15% of patients, the parent respondent differed between the
on- and off-dexamethasone measurement, all analyses were corrected
for parent’s sex.
All analyses were donewith IBM SPSS Statistics version 26.0.
3 RESULTS
3.1 Study population
One hundred fifty-one families provided written informed consent
(response rate 67%).25 Parents of 121 pediatric patients with ALL par-
ticipated at this time point. Patients (58% boys, median age 5.8 years)
were stratified to the SR group (25%) or MR group (75%). Mean time
since diagnosis was 12.9 ± 1.0 months at the first measurement for all
patients, and 14.1 ± 1.2 months at the second measurement (only MR
patients).
Parents completed a total of 191 measurements. Thirty measure-
ments were completed by parents of SR patients and 161 by parents
of MR patients (80 in a week with dexamethasone and 81 in a week
without dexamethasone). Within the MR group, 21 families completed
a single measurement and 70 families completed both measurements
(85% by the same parent) (Figure 2). Overall, respondents weremostly
mothers (80%), with a mean age of 39 ± 6 years. Parent and patient
characteristics are summarized in Table 1.
3.2 Description of parental sleep, distress,
and QoL
Table 2 shows SLP-9, distress, PCS and MCS scores for parents of
pediatric patients with ALL (SR andMR off-dexa combined) and Dutch
reference values. Compared to reference values, parents of pediatric
TABLE 1 Parent’s and patient’s characteristics
Standard-risk
patients
(n= 30)
Medium-risk
patients
(n= 91)
Child’s sex
Boys: n (%) 16 (53) 54 (59)
Girls: n (%) 14 (47) 37 (41)
Child’s age at measurement
Median years (range) 5.1 (3.0-16.5) 6.2 (2.4-19.0)
a
Child’s time since diagnosis
Mean time inmonths (SD) 13.0 (1.0) 12.9 (1.1)
a
Parent’s sex
Fathers: n (%) 3 (10) 17 (19)
a
Mothers: n (%) 27 (90) 74 (81)
a
Parent’s age at measurement
Mean years (SD) 38.0 (5.3) 39.5 (6.6)
a
a
Indicating n/median/mean at first measurement (MR patients).
TABLE 2 Mean scores of parents of pediatric patients with ALL
(standard-risk andmedium-risk off-dexamethasone) compared to
reference values
Parents of
patients with
ALL (off-dexa)
n= 101-111
Dutch
reference
P-value
(one-sided
t-test)
Mean SLP-9
score (SD)
34.0 (18.1) 21.7 (13.8) <.001
%Clinically
relevant
40 16 -
Mean distress
score (SD)
4.5 (2.4) 3.2 (2.7) <.001
%Clinical
distress
66 38 -
Mean PCS score
(SD)
53.7 (7.2) 52.5 (7.3)-54.8
(5.9)
a
-
Mean Z-score
(SD)
0.05 (1.0) 0 .6
%Clinically
impaired
13 16 -
MeanMCS
score (SD)
43.9 (10.2) 48.7 (10.3)-51.2
(8.3)
a
-
Mean Z-score
(SD)
−0.53 (1.1) 0 <.001
%Clinically
impaired
36 16 -
Abbreviations:ALL, acute lymphoblastic leukemia;MCS,mental component
summary; PCS, physical component summary; SLP-9, nine-item sleep prob-
lems index.
a
Age- and sex-specific reference values for healthy adults aged between 30
and 60 years lie in this range.
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TABLE 3 Regression analysis: mean scores of parents of standard- andmedium-risk patients (off-dexa), and corrected regression coefficients
(B, SE)
Parents of
childrenwith SR
ALL n= 26-30
Parents of childrenwith
MRALL (off-dexa)
n= 75-81 B (SE)
a
95%CI P-value
Mean SLP-9 score (SD) 34.8 (18.0) 33.7 (18.2) −0.76 (3.9) −8.52, 7.00 .8
%Clinically relevant 33 42 - - -
Mean distress score (SD) 3.52 (2.35) 4.82 (2.40) 1.29 (0.55) 0.19, 2.38 .02
%Clinical distress 54 71 - - -
Mean PCS score (SD) 54.6 (7.6) 53.3 (7.1) −1.58 (1.59) −4.74, 1.58 .3
Mean Z-score (SD) 0.21 (1.0) −0.01 (1.0) −0.23 (0.22) −0.66, 0.21 .3
%Clinically impaired 7 16 - - -
MeanMCS score (SD) 45.8 (10.6) 43.2 (10.1) −2.70 (2.25) −7.17, 1.77 .2
Mean Z-score (SD) −0.32 (1.1) −0.61 (1.0) −0.29 (0.23) −0.75, 0.17 .2
%Clinically impaired 24 40 - - -
Abbreviations: MCS, mental component summary; MRALL, medium-risk acute lymphoblastic leukemia; off-dexa, week without dexamethasone; PCS, physi-
cal component summary; SE, standard error; SLP-9, nine-item sleep problems index; SR ALL, standard-risk acute lymphoblastic leukemia.
a
Indicating the difference between parents of SR andMR patients, corrected for parent’s sex.
TABLE 4 Multilevel analysis: mean scores (SE) of parents of medium-risk patients on- and off-dexa, corrected for dependency of
measurements, and corrected regression coefficients (B, SE)
Parents of childrenwith
MRALL off-dexa
n= 75-81
Parents of childrenwith
MRALL on-dexa
n= 72-80 B (SE)
a
95%CI P-value
Mean SLP-9 score (SE) 33.9 (1.90) 34.8 (1.91) 1.47 (1.78) −2.07, 5.02 .4
Mean distress score (SE) 4.83 (0.28) 5.09 (0.28) 0.26 (0.39) −0.52, 1.04 .5
Mean PCS score (SE) 53.3 (0.77) 52.5 (0.77) −0.74 (0.86) 50.7, 61.2 .4
Mean Z-score (SE) −0.02 (0.11) −0.12 (0.11) −0.11 (0.12) −0.35, 0.14 .4
MeanMCS score (SE) 43.0 (1.15) 42.9 (1.15) −0.22 (1.16) −2.54, 2.09 .8
Mean Z-score (SE) −0.63 (0.12) −0.66 (0.12) −0.03 (0.12) −0.27, 0.20 .8
Abbreviations: MCS, mental component summary; MR ALL, medium-risk acute lymphoblastic leukemia; off-dexa, week without dexamethasone; on-dexa,
weekwith dexamethasone; PCS, physical component summary; SE, standard error; SLP-9, nine-item sleep problems index.
a
Indicating the difference between the on- and off-dexameasurements, corrected for parent’s sex.
patients with ALL reported significantly more sleep problems, higher
levels of distress, and lower mental QoL, but similar physical QoL.
Prevalence of clinically relevant sleep problems and mental QoL
impairment was 40% and 36%, respectively (compared to 16% [1 SD]
in the general population). Prevalence of clinical distress was 66%,
compared to 38% in parents of healthy children.
3.3 Comparison of parental sleep, distress, and
QoL between the SR and MR group
Table 3 shows SLP-9, distress, PCS and MCS scores for parents by risk
group. On average, parents of MR patients (off-dexa) reported higher
distress (mean score 4.8± 2.4) than parents of SR patients (mean score
3.5± 2.4; P= .02). Other outcomes did not significantly differ between
parents of SR andMR patients.
3.4 Comparison of parental sleep, distress,
and QoL on- versus off-dexa (MR group)
Table 4 shows SLP-9, distress, PCS and MCS scores for parents of MR
patients, with and without dexamethasone. Outcomes did not signifi-
cantly differ between on- and off-dexa.
4 DISCUSSION
This study aimed to assess sleep, distress, and QoL in parents of
pediatric patients with ALL during maintenance therapy. We found
that parents across both the SR and MR groups reported more
sleep problems, distress, and mental QoL impairment—as compared
to reference values. Unexpectedly, within the MR group, we did
not find differences in these parental outcomes between a week
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with and without dexamethasone. However, when comparing the
different risk groups, parents of MR patients report clinical dis-
tress levels more often than SR patients; hence, this might reflect
the differences between these risk groups in treatment intensity
and hospital visits, occurrence of complications, and prognostic
estimates.
Regarding treatment differences, patients with SR ALL receive oral
chemotherapy and visit the hospital only every 2-3weeks,whereasMR
patients haveweekly intravenous chemotherapy. For parents, frequent
hospital visits put a high strain on their working and social life, which
is stressful.34,35 Additionally, SR patients have a less toxic regimen
than MR patients, with fewer short- and long-term adverse effects.2
Also 5-year overall survival (OS) is better. In the previous DCOG ALL
treatment protocol (ALL10), OS was 99% for SR patients with an
event-free survival (EFS) of 93%, compared to 93%OS and 89% EFS in
MR patients.2 This difference in prognostic estimates between SR and
MR patients might also play a role in increased distress in parents of
MR patients. Yet this is not entirely supported by previous literature,
which documents that parents lack accurate prognostic awareness36
and their perceptionof prognosis does not influence theirwell-being.13
Another factor that we expected to influence outcomes in parents
of MR patients is the cyclic dexamethasone treatment. This treatment
may cause clinically relevant adverse psychological side effects in
up to 35% of pediatric patients with ALL,37 thus indirectly affecting
parental functioning as well. However, we did not find any additional
adverse effects of dexamethasone on the parental outcomes that we
measured. This may have been the case for several reasons. First, since
there is vast heterogeneity in the severity of side effects in patients,
it could be that families with the highest dexamethasone burden
did not participate in the on-dexa measurement. Furthermore, the
timing of the off-dexa measurement (just before the start of a new
dexamethasone block) may have been suboptimal because it might
be that we captured some anticipatory effects in parents from the
off-dexa week. Finally, it is possible that there is no specific additional
effect of dexamethasone on the (generic) parental outcomes that we
measured. If this is the case, there might still be an “overall” dexam-
ethasone strain, as reflected by the clinical distress levels in these
parents.
Several clinical implications can be derived from this study. First,
attention to the psychosocial well-being of parents should not stop
during maintenance treatment. Also, the parents of children in the
most favorable SR group should be sufficiently supported in the hos-
pital by the psychosocial team, even in this stable phase with relatively
low frequency of hospital visits. The urge for systematic screen-
ing for psychosocial risk throughout treatment phases has already
been stressed in the Standards of Psychosocial Care for Parents of
Children with Cancer, yet this is still not routine practice in many
hospitals.24,38
Second, considering the high prevalence (40%) of sleep problems,
the health burden that they entail and their chronic nature, early and
ongoing attention to sleep is justified.39,40 The sample described in this
study was also measured approximately 4 months after their child’s
diagnosis and prevalence of sleep problems at that time point was 50%
(data not yet published). This means that only a small proportion of par-
ents have recovered since the start of maintenance. Evidence-based
interventions to improve sleep exist (eg, cognitive behavioral therapy
for insomnia [CBT-I]), and these could perhaps be incorporated in this
relatively stable phase of treatment.41–43 CBT-I can be offered online
and might simultaneously improve distress and HRQoL, as shown in
other populations.44,45 Thus, CBT-I could be a brief and feasible inter-
vention that may have broad implications for caregiver functioning.
Third, although we did not capture an additional adverse effect of
dexamethasone treatment onparental functioning in theMRgroup,we
believe that it is still important to support families during the intensive
dexamethasone weeks. Ongoing education on common side effects
and guidance in handling children’s behavior may be useful. Besides,
in the future hydrocortisone addition during dexamethasone weeks
might alleviate side effects,37 but this is currently being investigated
further.
Finally, since child and parental functioning are closely related, opti-
mizing other supportive care for the child (eg, adequate pain manage-
ment and attention to child’s sleep) remains important.
This study has several limitations. First, no sex-specific reference
values were available on the MOS sleep scale. Since women report
more sleep problems than men33,40 and 80% of our sample were
mothers, this might have led to an overestimation of these problems.
Second, the SR group in our sample was small (n = 30); hence, it could
be that this study had insufficient power to find significant differences
with theMR group for some of the parental outcomes. Third, although
this was not a formal exclusion criterion, only one parent of a HR
patient participated in this study (excluded from analysis), which may
indicate participation bias and might have led to an underestimation
of parental difficulties. And finally, besides sex and risk group, we did
not take into account other factors, such as demographics, that could
potentially influence some of the parental outcomes. Future studies
should longitudinally assess parental outcomes in this population to
discover which parents aremost at risk for adverse outcomes.
In conclusion, sleep problems, distress, and mental QoL impairment
are prevalent among parents of children with ALL across both the SR
and MR groups, even in the relatively stable maintenance phase. Par-
ents of MR patients reported higher and clinical levels of distress as
compared to the SR group, but outcomes did not differ between aweek
with dexamethasone and a week without. Considering the overall out-
comes, we believe that this study mainly highlights the need for ongo-
ing psychosocial support across all risk groups and during the entire
treatment phase.
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